Twelve differentially expressed miRNAs (DEMs) in microarray analysis were further validated in nasal mucosa samples from 48 AR patients and 50 controls by qPCR assay. Individual nasal symptom score (INSS) and total nasal symptom score (TNSS) were used to evaluated the disease severity of AR. AR patients could be distinguished from controls according to the principal component analysis (PCA) plot analysis in the microarray, and 27 down-regulated and 51 up-regulated DEMs were identified by volcano plot. qPCR validation disclosed that miR-126-5p, miR-19a-5p and miR-26a-5p expression was up-regulated in AR patients compared with controls. Multivariate logistic regression displayed that miR-126-5p, miR-19a-5p and miR-26a-5p are independent predictive factors for AR risk, and receiver operating characteristic (ROC) analysis exhibited that the combination of miR-126-5p, miR-19a-5p and miR-26a-5p predicts the risk of AR with a high area under curve (AUC) of 0.866 (95% CI: 0.797-0.936). In addition, expression of miR-126-5p, miR-19a-5p and miR-181c-3p were positively correlated with TNSS.
Based on these results, researchers conclude that miRNA profiles can be used to distinguish AR patients from controls and the combination of miR-126-5p, miR-19a-5p and miR-26a-5p could serve as novel biomarker for AR risk.
ROC curve analysis was performed to evaluate the diagnostic value of the independent predict-ing miRNAs for AR risk in the multivariate logistic models in AR patients. A. The area under curve (AUC) of miR-126-5p was 0.685 (95% CI: 0.581-0.790); B. The AUC of miR-19a-5p was 0.742 (95% CI: 0.644-0.840); C. miR-26a-5p was 0.719 (95% CI: 0.619-0.819); D. The AUC of combination of miR-126-5p, miR-19a-5p and miR-26a-5p was 0.866 (95% CI: 0.797-0.936) with good sensitivity and specificity (89.6% and 70%, respectively) at the best cut-off point.
ROC curve analysis of 3 DEMs in AR patients